英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03696 英矽智能

香港特别行政区成立纪念日休市 06-30 16:08:07

39.620

-1.760

-4.25%

最高42.500	最低36.000	成交量5,619万
今开37.000	昨收41.380	日振幅15.71%
总市值226.48亿	流通市值226.48亿	总股本5.72亿
成交额21.65亿	换手率9.83%	流通股本5.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03696","market":"HK","secType":"STK","nameCN":"英矽智能","latestPrice":39.62,"timestamp":1782806887007,"preClose":41.38,"halted":0,"volume":56193091,"delay":0,"changeRate":-0.04253262445625918,"floatShares":571622000,"shares":571622000,"eps":-35.14166483637163,"marketStatus":"香港特别行政区成立纪念日休市","change":-1.76,"latestTime":"06-30 16:08:07","open":37,"high":42.5,"low":36,"amount":2164816473,"amplitude":0.157081,"askPrice":39.88,"askSize":500,"bidPrice":39.62,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-37.5733425371027,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782955800000},"marketStatusCode":7,"adr":0,"listingDate":1767024000000,"exchange":"SEHK","adjPreClose":41.38,"openAndCloseTimeList":[[1782783000000,1782792000000],[1782795600000,1782806400000]],"volumeRatio":6.310795594849422,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03696","defaultTab":"news","newsList":[{"id":"1160056126","title":"异动解读｜英矽智能盘中下跌11.12%，巨量限售股解禁日抛压集中释放","url":"https://stock-news.laohu8.com/highlight/detail?id=1160056126","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160056126?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:32","pubTimestamp":1782783159,"startTime":"0","endTime":"0","summary":"6月30日，英矽智能盘中下跌11.12%，报37.18港元/股，成交额8.42亿港元。消息面上，当日为公司巨量限售股正式解禁日，尽管公司早间公告CEO及首席科学官自愿将全部股权禁售期延长六个月至明年6月29日，但整体解禁规模巨大，市场抛压仍显著释放。此前该股自6月中旬累计涨幅接近50%，短期获利盘积累较重，叠加解禁日来临形成共振抛压。基本面方面，公司营收同比下滑34.48%，归母净亏损3.52亿美元，盈利拐点尚未显现。安永此前指出港股下半年将迎来新一波半新股解禁潮，市场对解禁压力保持警惕。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647585256","title":"英硅智能(03696.HK)：首席执行官作出自愿延长禁售承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2647585256","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647585256?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:30","pubTimestamp":1782783032,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647285585","title":"英硅智能(03696)：首席执行官作出自愿延长禁售承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2647285585","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647285585?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:30","pubTimestamp":1782783032,"startTime":"0","endTime":"0","summary":"各相关股东已订立禁售承诺，据此其同意于招股章程日期起直至上市日期满12个月当日止期间将不会直接或间接处置其持有的本公司任何股份。原禁售期将于2026年12月29日届满。于有关经延长禁售期内，相关股东将不会以任何方式直接或间接处置或以其他方式减持该等股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183968980","title":"异动解读｜英矽智能盘中下跌5.7%，巨量解禁倒计时最后一日抛压显著加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=1183968980","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183968980?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:00","pubTimestamp":1782698453,"startTime":"0","endTime":"0","summary":"6月29日，英矽智能盘中下跌5.7%，报37.48港元/股，成交额7440.82万港元。消息面上，公司巨量限售股解禁日为6月30日，市场对解禁抛压的担忧在最后交易日前集中释放。此前该股自6月中旬累计涨幅接近50%，短期获利盘积累较重，高位回吐压力持续。基本面方面，公司营收同比下滑34.48%，归母净亏损3.52亿美元，盈利拐点尚未显现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146971854","title":"异动解读｜英矽智能盘中下跌5.76%，巨量解禁倒计时叠加短期获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1146971854","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146971854?lang=zh_cn&edition=full","pubTime":"2026-06-26 10:50","pubTimestamp":1782442206,"startTime":"0","endTime":"0","summary":"6月26日，英矽智能盘中下跌5.76%，报42.88港元/股，成交额1.67亿港元。此前该股自上周三至6月25日累计涨幅接近50%，短期获利盘积累较重。基本面方面，公司营收同比下滑34.48%，归母净亏损3.52亿美元，盈利拐点尚未显现，短期内此前SK生物制药25亿美元合作及Rentosertib III期临床启动等利好已被充分定价，巨量解禁临近叠加高位获利回吐形成共振抛压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102570993","title":"港股直击 | AI制药迎重大突破，英矽智能午前飙升逾15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102570993","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102570993?lang=zh_cn&edition=full","pubTime":"2026-06-25 11:22","pubTimestamp":1782357733,"startTime":"0","endTime":"0","summary":"英矽智能( $英矽智能(03696)$ )午前飙升逾15%，上周三至今累计升幅接近50%。截至发稿，升14.08%，报48.14港元，成交额2.01亿港元。英矽智能近期宣布，即将启动公司首款AI驱动发现的候选药物Rentosertib（ISM001-055）口服治疗特发性肺纤维化的III期临床试验。Rentosertib是英矽智能目前进展最快的候选药物，其新颖的靶点和分子结构均由AI驱动发现和设计，具有全球首创（first-in-class）潜力，拟用于治疗特发性肺纤维化。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/5814d0565c481464234d720a50df6d4d","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/5814d0565c481464234d720a50df6d4d"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646516825","title":"港股异动 | 英硅智能(03696.HK)午前飙升逾15% 首款AI驱动发现的候选药物Rentosertib即将开启III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2646516825","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646516825?lang=zh_cn&edition=full","pubTime":"2026-06-25 11:14","pubTimestamp":1782357269,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184116563","title":"异动解读｜英矽智能盘中上涨5.64%，SK生物制药25亿美元合作利好持续发酵叠加券商研报催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1184116563","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184116563?lang=zh_cn&edition=full","pubTime":"2026-06-25 10:56","pubTimestamp":1782356215,"startTime":"0","endTime":"0","summary":"6月25日，英矽智能盘中上涨5.64%，报44.58港元/股，成交额8563.45万港元，延续近期强势表现。消息面上，公司于6月22日宣布与SK生物制药达成AI驱动的神经免疫疾病领域研发合作，潜在交易总金额超25亿美元，英矽智能有资格获得最高1800万美元首付款及近期里程碑付款，利好情绪持续发酵。此外，西南证券发布研报指出，公司核心管线Rentosertib已启动III期临床，作为全球首款完全由生成式AI发现并完成IIa期临床的候选药物，若成功上市有望成为颠覆性疗法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131641801","title":"异动解读｜英矽智能盘中上涨6.34%，SK生物制药25亿美元合作利好持续发酵叠加板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1131641801","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131641801?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:19","pubTimestamp":1782267551,"startTime":"0","endTime":"0","summary":"6月24日，英矽智能盘中上涨6.34%，报45.48港元/股，成交额7262.96万港元，延续近期强势表现。消息面上，公司于6月22日宣布与SK生物制药达成AI驱动的神经免疫疾病领域研发合作，潜在交易总金额超25亿美元，英矽智能有资格获得最高1800万美元首付款及近期里程碑付款，利好情绪持续发酵。板块层面，生命科学工具和服务板块今日整体走强，药明合联涨10.42%、药明康德涨8.18%、金斯瑞生物科技涨8.0%，板块共振进一步提振情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199135076","title":"英矽智能续升逾9%四连升，与SK生物制药达成AI驱动药物研发合作，潜在交易总金额超25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199135076","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199135076?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:23","pubTimestamp":1782181427,"startTime":"0","endTime":"0","summary":"$英矽智能$续升逾9%四连升，与SK生物制药达成AI驱动药物研发合作，潜在交易总金额超25亿美元。消息面上，据英矽智能官微消息，6月22日，英矽智能与总部位于韩国、以开创性药物研究引领生物技术创新的SK生物制药公司共同宣布，双方于BIO 2026国际大会前夕达成AI驱动的药物研发合作，将聚焦神经免疫性疾病领域，借助AI技术发现创新药物候选分子。","market":"us","thumbnail":"https://community-static.tradeup.com/news/06d4405ca948be865e2481effae665a5","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/06d4405ca948be865e2481effae665a5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"英矽智能续升逾9%四连升，与SK生物制药达成AI驱动药物研发合作，潜在交易总金额超25亿美元","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1150502656","title":"异动解读｜英矽智能盘中上涨5.95%，SK生物制药25亿美元合作利好延续推升股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1150502656","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150502656?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:49","pubTimestamp":1782179389,"startTime":"0","endTime":"0","summary":"6月23日，英矽智能盘中上涨5.95%，报42.72港元/股，成交额6188.72万港元，延续前一交易日强势表现。消息面上，公司于6月22日宣布与SK生物制药达成AI驱动的神经免疫疾病领域研发合作，潜在交易总金额超25亿美元，涵盖开发、监管及商业化里程碑付款，英矽智能有资格获得最高1800万美元首付款及近期里程碑付款。叠加此前纳入富时全球股票指数系列及ISM8969完成首例人体给药等多重催化，市场做多情绪延续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645396045","title":"英硅智能(03696)与SK生物制药达成一项价值高达25亿美元的神经免疫疾病领域的AI驱动研发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2645396045","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645396045?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:55","pubTimestamp":1782104111,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英硅智能 发布公告，英硅智能已与SK生物制药公司达成一项研发合作，旨在发掘AI驱动的针对中枢神经系统神经免疫疾病领域的创新候选药物。SK生物制药则将发挥其在神经免疫疾病领域深厚的研发与临床能力，主导所有合作计划后期开发及商业化推进。根据相关协议条款，英硅智能将有资格获得最高1800万美元的首付款及近期里程碑付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AIPO","CHAT","BK1141","03696","ARTY","AGIX","SK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109372003","title":"英矽智能与SK生物制药达成价值高达25亿美元的人工智能驱动研发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1109372003","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109372003?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:27","pubTimestamp":1782102433,"startTime":"0","endTime":"0","summary":"英矽智能与SK生物制药宣布达成一项人工智能驱动的研发合作，该合作潜在总价值最高可达25亿美元。双方将结合各自在人工智能药物发现和生物制药领域的专长，共同推进创新疗法的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180964583","title":"英矽智能潜在交易总价值超25亿美元，涵盖里程碑付款与特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1180964583","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180964583?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:27","pubTimestamp":1782102432,"startTime":"0","endTime":"0","summary":"英矽智能（Insilico Medicine Cayman Topco）的潜在交易总价值已超过25亿美元，其中包含了基于研发与商业进展的里程碑付款以及未来的特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144740693","title":"英矽智能将获得高达1800万美元的预付款及近期里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1144740693","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144740693?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:27","pubTimestamp":1782102431,"startTime":"0","endTime":"0","summary":"英矽智能将获得高达1800万美元的预付款及近期里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124627710","title":"异动解读｜英矽智能盘中下跌5.06%，巨量解禁倒计时临近压制反弹动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1124627710","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124627710?lang=zh_cn&edition=full","pubTime":"2026-06-22 11:27","pubTimestamp":1782098846,"startTime":"0","endTime":"0","summary":"6月22日，英矽智能盘中下跌5.06%，报36.4港元/股，成交额1.25亿港元。消息面上，尽管公司当日正式获纳入富时全球股票指数系列，但约4.53亿股限售股禁售期将于6月29日届满，占总股本81.25%，解禁规模约241亿港元，市场对潜在集中减持压力的担忧持续压制盘面。基本面方面，公司营收同比下滑34.48%，归母净亏损3.52亿美元，盈利拐点尚未显现，短期指数纳入带来的被动资金预期难以对冲解禁抛压情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644770581","title":"港股异动 | 英硅智能(03696)收涨近14% 本周正式进入中证指数系列 上市后已被纳入数个主要指数系列","url":"https://stock-news.laohu8.com/highlight/detail?id=2644770581","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644770581?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:11","pubTimestamp":1781770281,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英硅智能全天逆市走高，截至收盘，涨13.84%，报38.34港元，成交额3.38亿港元。消息面上，英硅智能获纳入中证指数系列，已于6月15日(本周一)起生效。值得注意的是，英硅智能宣布，与衡泰生物共同开发的ISM8969已达成首个临床里程碑，在I期临床研究中完成首例人体给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","03696","BK4588","BK4585","BK1141","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644777227","title":"【券商聚焦】西南证券：英硅智能(03696)核心管线III期临床启动 若成功上市有望成颠覆性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2644777227","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644777227?lang=zh_cn&edition=full","pubTime":"2026-06-18 14:22","pubTimestamp":1781763776,"startTime":"0","endTime":"0","summary":"金吾财讯 | 西南证券发布研报指，英硅智能 于2026年6月13日召开核心管线Rentosertib用于治疗特发性肺纤维化的III期临床试验研究者会议。Rentosertib是全球首款完全由生成式AI发现并完成IIa期临床的候选药物。若成功上市，有望成为颠覆性疗法。主要风险包括创新药研发和商业化不及预期、竞争加剧、行业政策变化。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984105","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK0276","BK4134","BK0028","BK0012","BK0183","600369","BK0188","03696","IPOS","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644776571","title":"港股异动 | 英硅智能(03696)逆市涨超6% Rentosertib三期临床会议召开 AI研发能力再获验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2644776571","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644776571?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:27","pubTimestamp":1781749648,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英硅智能逆市涨超6%，截至发稿，涨6.65%，报35.92港元，成交额4859.87万港元。消息面上，近日，英硅智能召开Rentosertib用于治疗IPF的III期临床试验研究者会议。据悉，Rentosertib是公司目前进度最快管线，也是全球首款完全由生成式AI发现和设计的、完成IIa期临床的候选药物，用于治疗特发性肺纤维化。该行表示，随着核心资产临床逐步推进，公司AI研发能力将得到进一步验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ARTY","VXUS","03696","CHAT","AGIX","BK1141","BK4585","BK4588","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160153897","title":"异动解读｜英矽智能盘中上涨5.05%，ISM8969首例人体给药催化延续叠加板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1160153897","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160153897?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:12","pubTimestamp":1781748721,"startTime":"0","endTime":"0","summary":"6月18日，英矽智能盘中上涨5.05%，报35.02港元/股，成交额3359.3万港元。消息面上，公司前一日公告与衡泰生物共同开发的ISM8969在I期临床研究中完成首例人体给药，达成首个临床里程碑，该药物为口服可穿透血脑屏障的NLRP3抑制剂，拟用于帕金森病等CNS疾病，英矽智能有权获得最高6600万美元预付款及里程碑付款，利好情绪延续。板块层面，生命科学工具和服务板块今日整体走强，药明生物涨3.28%、药明康德涨3.1%，板块共振提振情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://insilico.com","stockEarnings":[{"period":"1week","weight":-0.076},{"period":"1month","weight":-0.0471},{"period":"3month","weight":-0.3484},{"period":"6month","weight":0.0668},{"period":"1year","weight":0.6474},{"period":"ytd","weight":0.0668}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"英矽智能是一家主要从事人工智能在制药领域研发的公司。该公司致力于药物发现引擎的研发，并从事联合用药的发现和开发，包括疾病靶点识别、新分子数据生成以及临床试验结果预测。","exchange":"SEHK","name":"英矽智能","nameEN":"INSILICO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英矽智能(03696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英矽智能,03696,英矽智能股票,英矽智能股票老虎,英矽智能股票老虎国际,英矽智能行情,英矽智能股票行情,英矽智能股价,英矽智能股市,英矽智能股票价格,英矽智能股票交易,英矽智能股票购买,英矽智能股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英矽智能(03696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}